鲍　乐　袁　磊　张　辉　郭爱军江苏省徐州市肿瘤医院介入科，江苏徐州　221000

不同给药方案介入治疗原发性肝癌的临床疗效与安全性分析

鲍乐袁磊张辉郭爱军▲
江苏省徐州市肿瘤医院介入科，江苏徐州221000

目的探讨不同给药方案介入治疗原发性肝癌（HCC）的临床疗效和安全性。方法选取60例HCC患者并随机分为观察组和对照组，其中对照组采用奥沙利铂联合吉西他滨经导管肝动脉化疗栓塞（TACE）治疗，观察组采用奥沙利铂联合表柔比星TACE治疗，4～6周为1个疗程，评价两组治疗的总有效率及不良反应情况。结果经介入治疗后，观察组患者总有效率明显高于对照组（P＜0.05）；观察组患者白细胞减少率、血小板减少率、中性粒细胞减少率均显著低于对照组（P＜0.05）。观察组患者的2年期生存率明显高于对照组（P＜0.05）。结论奥沙利铂联合表柔比星行TACE术治疗HCC取得较好的疗效，且不良反应发生率较低，远期疗效更优，值得深入研究和推广。

介入治疗；原发性肝癌；临床疗效；安全性

［Abstract］Objective To investigate the c1inica1 efficacy and safety of interventiona1 therapy with different medications for hepatoce11u1ar carcinoma（HCC）.Methods A tota1 of 60 patients were random1y divided into contro1 group，which was given gemcitabine and oxa1ip1atin combined with TACE treatment，and observation group，which was treated with epirubicin p1us oxa1ip1atin combined with TACE treatment.The efficacy of treatment and side effects were compared between the two groups.Results Tota1 effective rate in the observation group was 1ower than that in the contro1 group （P＜0.05）.Reduction rates of the 1eukocyte，p1ate1et and neutrophi1 granu1ocyte in the observation group were higher than those in the contro1 group（P＜0.05）.2 year surviva1 rate of the patients in the observation group was higher than that of the contro1 group（P＜0.05）.Conclusion Oxa1ip1atin combined with epirubicin is effective and safe for patients with HCC，it's worthy of further investigation and c1inica1 app1ication.

［Key words］Interventiona1 therapy；Hepatoce11u1ar carcinoma；C1inica1 efficacy；Safety

原发性肝癌（hepatoce11u1ar carcinoma，HCC）是临床常见的恶性肿瘤，位居世界恶性肿瘤发病率第五位，其死亡率高居第三位［1，2］。对早期HCC患者行手术治疗为最佳选择，但因该病早期症状不明显，多数患者发现时已属晚期，错过了手术切除的最佳时机［3］。经导管肝动脉化疗栓塞术（transcatheter arteria1 chemoembo1ization，TACE）具有疗效确切、创伤小及适应证广等优点，是无法采取手术切除治疗的中晚期HCC患者的首选治疗手段［4］。奥沙利铂、表柔比星、吉西他滨对HCC均有一定的疗效，本文旨在探讨不同给药方案介入治疗HCC患者的临床效果和安全性，现报道如下。……